"目录号: HY-13682
Membrane Transporter/Ion Channel-
Mifamurtide(CGP19835; MTP-PE)可作用于骨肉瘤。
TRP Channel
相关产品
Rosiglitazone-Capsazepine-Capsaicin-SKF-96365 hydrochloride-Probenecid-HC-030031-PF-4840154-SAR7334-AMG 517-SB-705498-Icilin-GSK1016790A-RN-1734-ML204-HC-067047-
生物活性
Description
Mifamurtide(CGP19835; MTP-PE) is a drug against osteosarcoma.Target: OthersMifamurtide is an immunomodulator with antitumor effects that appear to be mediated via activation of monocytes and macrophages. Mifamurtide is generally well tolerated; adverse events attributed to administration of the drug include chills, fever, headache, nausea, and myalgias. Based on the available data, mifamurtide can be considered for inclusion in treatment protocols for localized osteosarcoma [1]. Mifamurtide has orphan drug status for the treatment of osteosarcoma in the US and EU [2].
Clinical Trial
NCT00631631
Millennium Pharmaceuticals, Inc.
Osteosarcoma
January 2008
NCT02441309
University of Oxford-Millennium: The Takeda Oncology Company-National Institute for Health Research, United Kingdom-Oxford University Hospitals NHS Trust-European Commission
Osteosarcoma
October 2014
Phase 2
NCT01194284
Millennium Pharmaceuticals, Inc.-Takeda
Osteosarcoma
December 2011
NCT01459484
Italian Sarcoma Group
Osteosarcoma
July 2011
Phase 2-Phase 3
NCT00000972
National Institute of Allergy and Infectious Diseases (NIAID)-Biocine
HIV Infections-HIV Seronegativity
Phase 1
NCT00001019
National Institute of Allergy and Infectious Diseases (NIAID)-Biocine
HIV Infections
Phase 1
NCT00000958
National Institute of Allergy and Infectious Diseases (NIAID)-Biocine
HIV Infections
Phase 1
NCT00001042
National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Phase 1
View MoreCollapse
References
[1].Frampton, J.E., Mifamurtide: a review of its use in the treatment of osteosarcoma. Paediatr Drugs, 2010. 12(3): p. 141-53.
[2].Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTP-PE, MLV 19835A, MTP-PE, muramyltripeptide phosphatidylethanolamine. Drugs R D, 2008. 9(2): p. 131-5.